1. Role of cytokines and anti-cytokine therapy in inflammatory diseases including rheumatic, inflammatory bowel, pulmonary and skin diseases
2. Clinical management issues in patients undergoing therapy with anti-TNF agents
3. Novel indications and novel treatment strategies utilizing anti-TNF therapy
4. Novel form of toxicity associated with anti-TNF therapy
5. Safety of anti-TNF therapy in chronic viral infections including HIV, HCV, and HBV

Opening and Deadline
The Call for Abstracts submittal process for the TNF & Beyond Summit opens March 15, 2005. The deadline for all abstract submittals is 5:00 pm (U.S. Eastern Daylight Time) on July 15, 2005.

Abstract Submittal and Confirmation
Please submit your abstract online at the following address: www.meetingassistant.com/TNF2005

Our online system provides a secure environment for abstract submittal. Each user creates their own unique username and password and provides their contact information. This secure access permits users to enter, review and edit their submitted abstract(s) online, right up to the closing deadline. The online submittal process (and the ability to go back to it for abstract review or edits) is your assurance that the abstract has been received.

E-mailed submissions receive an e-mail confirmation of receipt of abstract within 48 hours of submittal.

General Information
Each abstract will be reviewed by The TNF & Beyond Summit Steering Committee. Abstracts will be selected for poster presentation during assigned sessions at the TNF & Beyond Summit, with notification sent via email to the submitting (or presenting) author.

Authors may submit abstracts of completed work, work in progress, or work presented at a local or regional level. Abstracts presented elsewhere within the 12 months prior to the deadline of submission will be accepted. The primary author is responsible to obtain written consent from all authors and appropriate institutions prior to submitting an abstract.

Abstracts presented in this summit will not be published outside the Summit handbook and could therefore be submitted elsewhere for presentation.

Authors of accepted abstracts must be present at their posters during the assigned session(s) to allow for dialogue with summit participants.

Abstracts may not be sales presentations and must not imply any endorsement of any product or service by The Cleveland Clinic Foundation.

Review Process

1. Upon receipt, the abstract will be reviewed for compliance with the preceding instructions and assigned a number to ensure anonymity.
   
   
2. Abstracts are to be submitted and categorized by (but not limited to) the select topic categories previously mentioned.
   
   
3. Reviews of abstracts for acceptance and poster presentation will be performed by TNF & Beyond Steering Committee in the weeks following the deadline.
   
   
4. Primary authors will be notified by email of abstract acceptance the week of August 1, 2005.
   

Abstract Submission Guidelines

1. Please submit your abstract using the online submission system: www.meetingassistant.com/TNF2005
   
2. Authors may submit more than one abstract.
   
3. No more than 5 authors are permitted per abstract.
4. Authors of accepted abstracts will be notified and must register for the Summit in order to qualify for poster presentation, young investigators award, or subsequent abstract publication.
   • Young Investigators Awards: Top three abstracts submitted by trainees will be awarded $1,000 travel grant to defray some of the cost associated with attendance. Awards will be presented to recipients on the morning of the second day of the summit.
5. For abstracts with more than one author, the primary author should be the submitting person and must provide the following information:
   • Name (first and last)
   • Highest degree
   • Institution/hospital
   • Department
   • Address, city, state, zip/postal code, country
   • Telephone
   • Fax
   • E-mail
   • Primary Work Setting (private, academic, institution)
     
     
6. All correspondence, including notification of abstract acceptance and details for poster presentation, will be sent to the primary author via email. An abstract's primary author (or person submitting the abstract) shall be responsible for informing all contributing authors of any related correspondence.
7. Abstracts must be no more than 300 words (excluding the title and authors' names or tables). Abstracts that contain more than 300 words will not be reviewed. Abstracts may contain one table or one figure.
8. Display boards measuring 4' x 6' will be available during the Summit for poster display.
9. Accepted abstracts may be published in the summit handbook.
10. Abstracts will not be considered or reviewed unless all required fields are completed. Authors may edit abstracts online as long as they meet the submission deadline.
11. Abstracts must follow these font guidelines:
    
    

    Title:	10 pt Times (in BOLD CAPITAL letters)
    Authors:	new line, 9 pt Times upright
    Affiliations:	new line, 9 pt Times upright
    Text:	leave blank line before beginning the text, 9 pt Times upright
    Tables:	8 pt Times

    
    
12. The information needed for the abstract heading (for each author) should include author's first name, surname (last name), institution name, city, state and country (if non-USA). The abstract's title should clearly indicate the nature of the subject.
13. If the work is in progress, include all planned methods, projected sample size, and analyses.
14. To be considered for review, abstracts must be submitted no later than 5:00 pm (U.S. Eastern Standard Time) on July 15, 2005.

For Additional Information

Please contact the Abstract Coordinator, UNITECH Communications® at (800) 238-6750 or (216) 297-7330.